Clinicopathological study of fractional exhaled nitric oxide dynamics and intratumoral inducible nitric oxide synthase expression in primary lung cancer patients.

ABSTRACT:

Background

Inducible nitric oxide synthase (iNOS) is expressed in non-small cell lung cancer (NSCLC) tumor cells and contributes to tumorigenesis. Nitric oxide, an indicator of airway inflammation, is concurrently produced in the airway epithelium. However, the interrelationships and predictive importance of iNOS remain unclear. This study aimed to investigate whether iNOS could serve as a novel biomarker for NSCLC.

Methods

Immunohistochemical analysis of iNOS expression in the tumor cells of 101 consecutive patients with NSCLC undergoing lung resection was conducted. The fractional exhaled nitric oxide (FeNO) levels were evaluated pre- and postoperatively using a clinically applied respiratory function testing device. iNOS expression was assessed by immunochemical staining

SUBMITTER: Okamoto K 

PROVIDER: S-EPMC11483420 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature